Nasdaq btai.

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Positive Topline Results for TRANQUILITY II; Possible Trial Conduct Issues at One Clinical Site On June 29, 2023 ...Following a 60% decline over last year, recent gains may please BioXcel Therapeutics, Inc. (NASDAQ:BTAI) institutional owners Read full article [email protected] (Simply Wall St)On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) said the FDA has accepted for filing the new drug application for BXCL501, its investigational, orally dissolving thin film formulation of dexmedetomidine ...According to the issued ratings of 7 analysts in the last year, the consensus rating for BioXcel Therapeutics stock is Hold based on the current 5 hold ratings and 2 buy ratings for BTAI. The average twelve-month price prediction for BioXcel Therapeutics is $23.88 with a high price target of $40.00 and a low price target of $11.00.

NEW HAVEN, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioXcel Therapeutics Inc (Symbol: BTAI), where a total of 14,591 contracts have traded ...BioXcel Therapeutics, Inc. BTAI is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.

NEW HAVEN, Conn., Aug. 14, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. 2017. 183. Vimal Mehta. https://www.bioxceltherapeutics.com. BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or ...Conversely, if the price of BTAI breaks below NASDAQ:BTAI Technical Analysis for NASDAQ:BTAI : If the price of BTAI breaks above the bullish line of $11.61, it may indicate a bullish signal, suggesting potential upward price movement. In this scenario, the target price could be set at $16.80. Conversely, if the price of BTAI breaks below NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to discuss BXCL502, a potential treatment for chronic agitation in dementia, along with other emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid …

NEW HAVEN, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for ...Find the latest Earnings Report Date for TG Therapeutics, Inc. Common Stock (TGTX) at Nasdaq.com.As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.

Based on analysts offering 12 month price targets for BTAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Based on analysts offering 12 month price targets for BTAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .add_box. NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Jun 29, 2023 · BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ... NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

Fintel reports that on May 30, 2023, HC Wainwright & Co. reiterated coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 187.47% Upside. As of ...NEW HAVEN, Conn., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced proof-of-concept data from its Phase 1b study of ...

NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Shares of BioXcel Therapeutics ( BTAI -2.56%) were down 62% at 11 a.m. on Thursday after the company announced phase 3 trial results for Alzheimer's disease–related agitation therapy BXCL501 ...Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.About. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...BioXcel Therapeutics Inc Follow Share $3.93 After Hours: $3.90 (0.76%) -0.030 Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc …NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023.

Jul 5, 2023 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioXcel Therapeutics Inc (Symbol: BTAI), where a total of 14,591 contracts have traded ...

NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Positive Topline Results for TRANQUILITY II; Possible Trial Conduct Issues at One Clinical Site On June 29, 2023 ...Shares of the commercial-stage biopharma BioXcel Therapeutics ( BTAI 16.29%) were up by 10.3% on heavy volume as of 3:29 p.m. ET Monday afternoon. The big gain came after the drugmaker reported ...BioXcel Therapeutics (Nasdaq:BTAI) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech BioXcel Therapeutics …NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...NEW HAVEN, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...NEW HAVEN, Conn., July 22, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s ...NEW HAVEN, Conn., Aug. 14, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

Dec 1, 2023 · When is BioXcel Therapeutics's earnings date? BioXcel Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off last year's report dates. Learn more on BTAI's earnings history. Find the latest Earnings Report Date for TG Therapeutics, Inc. Common Stock (TGTX) at Nasdaq.com.More specifically, Citadel Investment Group was the largest shareholder of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), with a stake worth $32.5 million reported as of the end of September.Instagram:https://instagram. robotics etfsnvda stock price targetforex robotfutures trading lessons add_box. NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ... 3x short dowbest broker for cryptocurrency trading Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing. sls life On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.Some companies are tagging along, including BioXcel Therapeutics (NASDAQ: BTAI), a small-cap biotech stock. BioXcel remains deep in the red for the year, but ongoing developments have helped fuel ...Real time BioXcel Therapeutics (BTAI) stock price quote, stock graph, news & analysis.